Search
bromfenac (Duract, Xibrom)
Tradenames: Duract. FDA approved in 1997. Withdrawn from US market in 1998 [2]. Ophthalmic agent: (Xibrom), FDA approved 2005
Indications: post-operative inflammation & eye pain
Dosage: 25 mg PO every 6-8 hours for no more than 10 days.
Tabs: 25 mg
Adverse effects:
-> hepatotoxicity*
* reason for US market withdrawal
Interactions
drug interactions
drug adverse effects of NSAIDs
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
non-steroidal anti-inflammatory agent (NSAID)
Properties
INHIBITS: cyclooxygenase
MISC-INFO: elimination route LIVER
KIDNEY
pregnancy-category C
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- Tarascon Pharmacopoeia,
Tarascon Publishing, Loma Linda CA, 1998
- Fresno Bee, Dec. 2000
- Prescriber's Letter 13(2): 2006
Detail-Document#: 220215
(subscription needed) http://www.prescribersletter.com